Nervenheilkunde 2012; 31(01/02): 67
DOI: 10.1055/s-0038-1628208
A. Meiβner: Omega-3-Fettsäuren
Schattauer GmbH

Literatur zum Artikel A. Meiβner

Further Information

Publication History





Publication Date:
23 January 2018 (online)

 

 
  • Literatur

  • 1 Amminger GP. et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry 2010; 67 (02) 146-154.
  • 2 Appleton KM. et al. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsatured fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757-770.
  • 3 Bahadori B. et al. Omega-3 fatty acids infusions as adjuvant therapy in rheumatoid arthritis. J Parenter Enteral Nutr 2010; 34: 151-155.
  • 4 Calder PC. N-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci 2004; 107: 1-11.
  • 5 Calder PC. Omega-3-Fettsäuren. Ars medici 2009; 4: 159-164.
  • 6 Carney RM. et al. Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosomatic Medicine 2010; 72: 748-754.
  • 7 Cunnane S. et al. Recommendations for intakes of polyunsaturated fatty acids in healthy adults. ISSFAL 2004; Newsl 11: 12-25.
  • 8 Dangour AD. et al. Fish consumption and cognitive function among older people in the UK: Baseline Data from the OPAL study. J Nutr Health Aging 2008; 13: 198-202.
  • 9 Freeman MP. et al. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67: 1954-1967.
  • 10 Gracious BL. et al. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar disord 2010; 12: 142-154.
  • 11 Hedelin M. et al. Dietary intake of fish, omega-3, omega-6 polyunsatured fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33.000 women from the general population. BMC Psychiatry 2010; 10: 38.
  • 12 Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351: 1213.
  • 13 Hibbeln JR. et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 2007; 369: 578-585.
  • 14 Huss M. et al. Supplementation of polyunsatured fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems – an observational cohorty study. Lipids in Health and Disease 2010; 9: 105.
  • 15 Investigators GP. Dietary supplementation with n-3 polyunsatured fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
  • 16 Jazayeri S. et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42: 192-198.
  • 17 Jazayeri S. et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. J Psychiatry Res 2010; 178: 112-115.
  • 18 Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clin Interv Aging 2010; 5: 45-61.
  • 19 Kiefer I. et al. Einfluss von Functional Food und Nahrungsergänzungen auf kardiovaskuläre Risikofaktoren. J Kardiol 2003; 10: 418-423.
  • 20 Kirby A. et al. A double-blind, placebo-controlled study investigating the effects of omega-3 supplementation in children aged 8–10 years from a mainstream school population. Res Dev Disabil 2010; 31: 718-730.
  • 21 Kirby A. et al. Children’s learning and behaviour and the association with cheek cell polyunsaturated fatty acid levels. Res Dev Disabil 2010; 31: 731-742.
  • 22 Laino C H. et al. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine. Eur J Pharmacol 2010; 648: 117-126.
  • 23 Levant B. N-3 (Omega-3) fatty acids in postpartum depression: Implications for prevention and treatment. Depression research and treatment 2011; 467: 349.
  • 24 Lieb K. et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Brit J Psychiatry 2010; 196: 4-12.
  • 25 Lin P. et al. A meta-analytic review of polyunsatured fatty acid compositions in patients with depression. Biol Psychiatry 2010; 68: 140-147.
  • 26 Maringer B. et al. Omega-3-Fettsäuren bei Psoriasis – Ein systematischer Review der Effektivität. Aktuel Ernahrungsmed 2009; 34 (04) 195-200.
  • 27 Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsatured fatty acid supplementation in depression: Evidence from a meta-analysis of randomized controlled trials. J Am C Nutr 2009; 28: 525-542.
  • 28 Meißner A. Mensch, was nun? Wie wir der ökologischen Krise begegnen – können. Münster: Monsenstein & Vannerdat; 2009: 41
  • 29 Morley JE, Banks WA. Lipids and cognition. J Alzheimers Dis 2010; 20: 737-747.
  • 30 Noaghiul MD, Hibbeln R. Cross-National Comparisons of Seafood Consumption and Rates of Bipolar Disorders. Am J Psychiatry 2003; 160: 2222-2227.
  • 31 Reinke C. PUFA mit Omega-3-Fettsäuren – essen-ziell für kluge Köpfe. SZE 2009; 3: 48-50.
  • 32 Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandines, Leukotrienes and Essential Fatty Acids 2000; 63: 1-9.
  • 33 Riemer S. et al. Lowered Omega-3-PUFAs are related to major depression, but not to somatization syndrome. J Affect Disord 2010; 123: 173-180.
  • 34 Ritch CR. et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol 2007; 177: 97-1071.
  • 35 Schuchardt JP, Hahn A. Essenzielle Fettsäuren und Hirnfunktion bei Kindern. Deutsche Apotheker Zeitung 2008; 10: 56-64.
  • 36 Servan-Schreiber D. Die Neue Medizin der Emotionen. München: Kunstmann; 2004
  • 37 Stoffers J. et al. Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews, Issue 6 2010 ; Art. No.: CD005653. DOI: 10.1002/14651858.CD 005653.pub2.
  • 38 Stoll AL. et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
  • 39 Stordy B, Nichool M. The LCP solution: The remarkable nutritional treatment for ADHD, dyslexia, and dyspraxia. New York: Ballantine Books; 2000
  • 40 Sublette ME. et al. Omega-3 polyunsatured essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 2006; 163: 100-1102.
  • 41 Surette ME. The science behind dietary omega-3 fatty acids. CMAJ 2008; 178: 177-180.
  • 42 Taubert D. Omega-3-Fettsäuren in der Sekundärprävention der KHK. Vortrag bei der Fortbildungsveranstaltung der edi (Ernährung, Diätetik, Infusionstherapie), Berlin:: 2009 www.dgem.de/ma/terial/pdfs/edi09/edi_09_Taubert%20Omega-3-Fettsaeuren.pdf.
  • 43 Taepavarapruk P, Song C. Reductions of acetylcho-line release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1ß administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem 2009; 112: 1054-1064.
  • 44 Turner D. et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17: 336-345.
  • 45 Wilhelm M. et al. Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am Heart J 2008; 155: 971-977.
  • 46 Williams CD. et al. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res 2011; 31: 1-8.